POLAND - 2025/01/25: In this photo illustration, the Sarepta Therapeutics company logo is seen ... More displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images) Sarepta's current distressed valuation makes it an attractive acquisition candidate for larger pharmaceutical companies seeking gene therapy capabilities. The company's expertise, intellectual property, and market-leading position in Duchenne treatments could command significant premiums in a take ...

NEW YORK, July 29, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/sarepta-lawsuit-submissio ...

Shares of Sera Therapeutics up by about 36% in the pre-market. The company says that it will resume shipping Alvdus, that's a muscular disorder gene therapy to patients who can walk. Last week, the FDA recommended a pause in shipments because of serious safety concerns after three deaths of patients who were on this who were on serene therapies. This past weekend, there were reports of a death of another child on Avdus, but the death, the FDA now says, was unrelated to the gene therapy. In a statement, Surr ...

Group 1 - Major stock index futures are showing positive movement, with Dow futures up 0.16%, S&P 500 futures up 0.24%, and Nasdaq futures up 0.40% [1] - Technology stocks are mostly rising, with Nvidia up over 1.5% and AMD and Advanced Micro Devices up over 1% [2] - Some Chinese concept stocks are experiencing significant gains, with Li Auto up over 4%, Global Data up over 3%, and Miniso and NIO up over 1% [2] Group 2 - Nvidia reportedly placed an order for 300,000 H20 chips from TSMC, contributing to its pre-market rise of over 1.5% [4] - Sarepta Therapeutics saw a pre-market surge of over 40% after the FDA authorized the resumption of its gene therapy Elevidys for treating Duchenne muscular dystrophy [5] - Apple announced the closure of its first direct store in China, located in Dalian, due to the departure of several retailers from the shopping center, with the store set to close on August 9, 2025 [6] Group 3 - Ford has signed a new $3 billion term loan agreement, which will last until July 28, 2026, with drawn loans maturing on December 31, 2028 [8] - Stellantis reported a 13% year-over-year decline in net revenue for the first half of 2025, totaling €74.3 billion, primarily due to declines in North America and Europe, resulting in a net loss of €2.3 billion compared to a net profit of €5.6 billion in the same period last year [9]

来源：格隆汇APP 格隆汇7月29日丨生物技术公司Sarepta Therapeutics盘前暴涨超45%，公司获FDA批准恢复基因疗法 Elevidys用于杜氏肌营养不良症(DMD)治疗。 ...

Core Viewpoint - Class actions have been initiated on behalf of stockholders of Hims & Hers Health, Inc. and Sarepta Therapeutics, Inc. due to alleged misleading statements and undisclosed material facts regarding their business operations and prospects [1][4]. Hims & Hers Health, Inc. (NYSE: HIMS) - Class period is from April 29, 2025, to June 23, 2025, with a lead plaintiff deadline of August 25, 2025 [2]. - Allegations include that Hims engaged in deceptive promotion of illegitimate versions of Wegovy, risking patient safety and jeopardizing collaboration with Novo Nordisk [2][3]. - Defendants are accused of making false statements about the partnership with Novo, which was supposed to ensure access to Wegovy for Hims subscribers, and misrepresenting the offerings of compounded semaglutide products [3]. Sarepta Therapeutics, Inc. (NASDAQ: SRPT) - Class period is from June 22, 2023, to June 24, 2025, with a lead plaintiff deadline of August 25, 2025 [4]. - The complaint alleges that Sarepta misled investors about the safety and revenue outlook of its gene therapy ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [4]. - Specific allegations include failure to disclose significant safety risks associated with ELEVIDYS, misleading statements about trial protocols, and the potential for regulatory scrutiny due to adverse events [4]. - Following a safety update on March 18, 2025, where a patient died after treatment, Sarepta's stock price fell by $27.81 per share, or 27.44% [5]. - Subsequent disclosures of additional patient deaths led to further declines in stock price, including a drop of $15.24 per share, or 42.12%, on June 15, 2025 [6].

SAN DIEGO, July 28, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, inclusive (the “Class Period”), have until Monday, August 25, 2025 to seek appointment as lead plaintiff of the Sarepta class action lawsuit. Captioned Dolgicer v. Sarepta Therapeutics, Inc., No. 25-cv-05317 (S.D.N.Y.), the Sarepta class action lawsuit charges Sarepta as well as certain of Sarepta ...

In a major win for Sarepta, US regulators are recommending that patients who can walk be allowed to take its gene therapy Elevidys again https://t.co/lnGkzEsubE ...

美国食品药品管理局（FDA）：调查结果显示，八岁男孩的死亡与Sarepta Therapeutics的基因疗法 Elevidys无关。 ...

Core Viewpoint - A class action securities lawsuit has been filed against Sarepta Therapeutics, Inc. alleging securities fraud related to the company's gene therapy product, ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Sarepta made false statements regarding the safety of ELEVIDYS, concealing significant risks to patients [2]. - It is alleged that the trial protocols for ELEVIDYS failed to identify severe side effects, which could lead to the halting of recruitment and dosing in trials, attracting regulatory scrutiny [2]. - The severity of adverse events from ELEVIDYS treatment is said to have misled investors regarding the therapy's approval prospects [2]. Group 2: Investor Information - Investors who suffered losses during the specified period (June 22, 2023, to June 24, 2025) have until August 25, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require investors to incur any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].